Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 15:28 ET | Source: NMDP

A Rockstar Puppet and a Life-Saving Message: NMDP Launches New Awareness Campaign to Help More Patients Receive Cell Therapy

NMDP launched a new PSA called "Know Your N-M-D-Ps,” featuring a puppet rock star, to raise awareness of blood stem cell transplants.
November 03, 2025 07:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with...
October 14, 2025 14:10 ET | Source: KuicK Research

Lymphoma Antibody Drug Conjugates Treatment Market FDA Approved Drugs Clinical Trials Lymphoma ADC Market Opportunity Insight

Delhi, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Global Lymphoma Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales and Clinical Trials Insight 2030 Report Finding &...
September 02, 2025 07:59 ET | Source: Research and Markets

Hemato-Oncology Testing Market Size, Share & Trends Analysis Report 2025-2030 Featuring Key Players Roche, Abbott, EntroGen, Qiagen, and Cepheid (Danaher) Among Others

Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The "Hemato-Oncology Testing Market Size, Share & Trends Analysis 2025-2030" has been added to ResearchAndMarkets.com's offering. The global hemato...
August 28, 2025 08:00 ET | Source: Marker Therapeutics

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
August 26, 2025 07:00 ET | Source: Marker Therapeutics

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating...
July 30, 2025 08:00 ET | Source: Marker Therapeutics

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
July 24, 2025 05:59 ET | Source: Research and Markets

Diffuse Large B-cell Lymphoma Market Research Report 2025-2035 | Personalized Medicine and Precision Treatment Trends in DLBCL

Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "Diffuse Large B-cell Lymphoma Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to ...
May 12, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight

New York, USA, May 12, 2025 (GLOBE NEWSWIRE) -- Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight The blood cancer market...
April 08, 2025 08:00 ET | Source: Recursion Pharmaceuticals

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first...